The economic implications of generic substitution of antiepileptic drugs: A review of recent evidence

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 14, 2009, Pages 2317-2328

  Duh, Mei Sheng ^a   Cahill, Kevin E ^a   Paradis, Pierre Emmanuel ^b   Cremieux, Pierre Y ^a   Greenberg, Paul E ^a  

^a ANALYSIS GROUP   (United States)

^b Groupe d'Analyse   (Canada)

Author keywords

Antiepileptic drugs; Bioequivalence; Economics; Generic substitution; Review

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; GENERIC DRUG; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; ZONISAMIDE;

ANTICONVULSANT THERAPY; AREA UNDER THE CURVE; BIOEQUIVALENCE; BIPOLAR DISORDER; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DISEASE CONTROL; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG UTILIZATION; ECONOMIC EVALUATION; EPILEPSY; FEBRILE CONVULSION; FIBROMYALGIA; FOOD AND DRUG ADMINISTRATION; HOSPITALIZATION COST; HUMAN; LONG TERM CARE; MANIA; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; NEUROPATHIC PAIN; PANIC; PATENT; POSTHERPETIC NEURALGIA; PRESCRIPTION; PROSPECTIVE PRICING; QUALITATIVE ANALYSIS; REVIEW; SEIZURE; STENOSIS, OCCLUSION AND OBSTRUCTION; TREATMENT OUTCOME; TRIGEMINUS NEURALGIA;

ANTICONVULSANTS; CANADA; COST-BENEFIT ANALYSIS; DRUGS, GENERIC; EPILEPSY; HEALTH CARE COSTS; HUMANS; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME; UNITED STATES;

EID: 70349378495     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903140525     Document Type: Review

References (53)

1. Liow K, Barkley GL, Pollard JR, et al. American Academy of Neurology. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 2007;68:1249-1250
2. AMCP board of directors, where we stand on generic drugs. Available from: http://www.amcp.org/amcp. ark?p=AA2D6237. [Accessed 16 April 2009]
3. US Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations (Orange Book), 28th edition. 2008. Available from: http://www.fda.gov/cder/orange/obannual. pdf. [Accessed 2 December 2008]
4. Berg M. What's the problem with generic antiepileptic drugs? A call to action. Neurology 2007;68:1245-1246 (Pubitemid 46625966)
5. Feely M, Crawford P, Krämer G, Guberman A. Risk management in epilepsy: generic substitution and continuity of supply. Eur J Hospital Pharm Sci 2005;11(4):83-87
6. Crawford P, Feely M, Guberman A, Kramer G. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 2006;15(3):165-176
7. LeLorier J, Duh MS, Paradis PE, et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Contemporary issues in neurologic practice. Neurology 2008;70:2179-2186
8. Kramer G, Biraben A, Carreno M, et al. Current approaches to the use of generic antiepileptic drugs. Epilepsy Behav 2007;11:46-52 (Pubitemid 47087191)
9. Berkovic SF. Treatment with anti-epileptic drugs. Aust Fam Physician 2005;34:1017-1020
10. "Prescription Drug Trends", Kaiser family foundation prescription drugs trends fact sheet, September, 2008: p. 1. Available from: http://www.kff.org/ rxdrugs/3057.cfm. [Accessed 11 December 2008]
11. Catlin A, Cowan C, Hartman M, Heffler S, and the National Health Expenditure Accounts Team. National Health Spending in 2006: a year of change for prescription drugs. Health Aff 2008;27(1):14-29
12. Express Scripts, 2007 Drug Trend Report, April 2008:p. 3. Available from: http://www.express-scripts.com/ industryresearch/industryreports/. [Accessed 11 December 2008]
13. Medco, Drug Trend Report, 2007;9:8-10. Available from: http://medco.mediaroom. com/index.php?s=64&cat=5. [Accessed 11 December 2008]
14. Grabowski H. Competition between generic and branded drugs. chapter 8. In: Sloan FA, Hsieh CR, editor, Pharmaceutical innovation. New York, NY: Cambridge Press, 2007: p. 154, 158
15. LeLorier J, Duh MS, Paradis PE, et al. Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting. Curr Med Res Opin 2008;24(4):1069-1081 (Pubitemid 351579165)
16. Papsdorf T, Ablah E, Ram S, et al. Patient perception of generic antiepileptic drugs in the Midwestern United States. Epilepsy Behav 2008. In press
17. American Medical Association. Generic substitution of narrow therapeutic index drugs. Available from: http://www.ama-assn.org/ama/pub/ category/17731.html. [Accessed on 24 December 2008]
18. Privitera MD. Generic antiepileptic drugs: current controversies and future directions. Epilepsy Curr 2008;8(5):113-117
19. Greenberg P. Does generic substitution always make sense? J Med Econ 2008;11:547-553
20. Borgherini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003;25(6):1578-1592 (Pubitemid 36801937)
21. Guberman A, Corman C. Generic substitution for brand name antiepileptic drugs: a survey. Can J Neurol Sci 2000;27:37-43 (Pubitemid 30126864)
22. Wilner AN. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav 2004;5:995-998
23. Meredith PA. Generic drugs: therapeutic equivalence. Drug Saf 1996;15:233-242
24. Meredith P. Bioequivalence and other unresolved issues in generic substitution. Clin Ther 2003;25:2875-2890 (Pubitemid 37510596)
25. Begley CE, Beghi E. The economic cost of epilepsy: a review of the literature. Epilepsia 2002;43(4):3-9 (Pubitemid 34627709)
26. EUCARE, Brodie MJ, deBoer HM, Johannessen SI (eds.). European white paper on epilepsy. Epilepsia 2003;44 (Suppl 6):1-88
27. Banahan BF, Bonnarens JK, Bentley JP. Generic substitution of NTI drugs: issues for formulary committee consideration. Formulary 1998;33:1082-1096
28. Benet LZ, Goyan JE. Bioequivalence and narrow therapeutic index drugs. Pharmacotherapy 1995;15:433-440
29. Sander JW. The use of antiepileptic drugs - principles and practice. Epilepsia 2004;45(6):28-34 (Pubitemid 39350327)
30. Kwan P, Brodie MJ. Combination therapy in epilepsy: when and what to use. Drugs 2006;66(14):1817-1829 (Pubitemid 44584005)
31. Yeager KA, DiIorio C, Shafer PO, et al. The complexity of treatments for persons with epilepsy. Epilepsy Behav 2005;7:679-686
32. Lamy PP. Generic equivalents: issues and concerns. J Clin Pharmacol 1986;26:30916
33. Besag FM. Is generic prescribing acceptable in epilepsy? Drug Saf 2000;23(3):173-182
34. Tompson DJ, Ali I, Oliver-Willwong R. Steady-state pharmacokinetics of lamotrigine when converting fromat wice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (the COMPASS study). Epilepsia 2008;49:410-417 (Pubitemid 351294522)
35. Leppik IE. Epilepsy in the elderly. Epilepsia 2006;47(Suppl 1):65-70
36. Anonymous. For and against generic prescribing. Drug Ther Bull 1987;25:93-95
37. Sachdeo RC, Belendiuk G. Generic versus branded carbamazepine. Lancet 1987;I:1432
38. Jumoa-as A, Bella I, Craig B, et al. Comparison of steady state blood levels of two carbamazepine formulations. Epilepsia 1989;30:67-70 (Pubitemid 19056015)
39. Gilman JT, Alvarez LA, Duchowny M. Carbamazepine toxicity resulting from generic substitution. Neurology 1993;(43):2696-2697 (Pubitemid 24004571)
40. Vadney VJ, Kraushaar KW. Effects of switching from depakenetogeneric valproic acid on individuals with mental retardation. Ment Retard 1997;35:468-472
41. Jobst BC, Holmes GL. Prescribing antiepileptic drugs: should patients be switched on the basis of cost? CNS Drugs 2004;18:617-628
42. Duh MS, Andermann F, Paradis PE, et al. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine. Dis Manag 2007:10(4):216-225 (Pubitemid 47403497)
43. Duh MS, Paradis PE, Latrémouille-Viau D, et al. The risks and costs of multiple-generic substitution of topiramate. Neurology 2009. In press
44. Paradis PE, Latrémouille-Viau D, Moore Y, et al. Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries. 2009, manuscript in preparation
45. Helmers S, Paradis PE, Manjunath R, et al. The direct health care cost burden associated with the use of generic antiepileptic drugs in the United States, manuscript in preparation
46. Murray MI, Halpern MT, Leppik IE. Cost of refractory epilepsy in adults in the USA. Epilepsy Res 1996;23:139-148
47. Berg MJ, Gross RA, Haskins LS, et al. Generic substitution in the treatment of epilepsy: patient and physician perceptions. Epilepsy Behav 2008;13:693-699
48. EmedTV. Available from: http://epilepsy.emedtv.com. [Accessed 19 December 2008]
49. Epilepsy.com. Available from: http://epilepsy.com/epilepsy/history. [Accessed 19 December 2008]
50. Heaney D, Sander JW. Antiepileptic drugs: generic versus branded treatments. Lancet Neurol 2007;6:465-468 (Pubitemid 46551869)
51. International AED name database. Available from: http://www.ilae.org/ visitors/centre/ aeds/epilepsy. [Accessed 19 December 2008]
52. RxNews. Primary patent expirations for selected high revenue drugs. Available from: http://www.prescriptionsolutions.com/c/ rxnews/rxnews-view. asp?Article=674&type=19. [Accessed 19 December 2008]
53. Argumosa A, Herranz JL. The clinical and economic impact of generic drugs in the treatment of epilepsy. Rev Neurol 2005;41:45-49 (Pubitemid 350020953)